HELP Therapeutics develops allogeneic off-the-shelf cell therapies using induced pluripotent stem cells (iPSCs) to treat degenerative diseases, particularly in the cardiovascular and nervous systems. Their focus on safe and effective cell products aims to improve patient outcomes in conditions like end-stage heart failure.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for degenerative diseases, particularly in the cardiovascular and nervous systems, often fall short of providing effective and long-lasting solutions. End-stage heart failure and other severe conditions lack therapies that can regenerate damaged tissues and restore function.
Solution
HELP Therapeutics develops allogeneic, off-the-shelf cell therapies derived from induced pluripotent stem cells (iPSCs) to address degenerative diseases. Their approach focuses on creating safe, effective, and affordable cell-based products designed to regenerate damaged tissues and improve patient outcomes. The company's research and development pipeline targets diseases within the cardiovascular and nervous systems, with a focus on conditions like end-stage heart failure.
Target Audience
The primary target audience includes patients suffering from degenerative diseases, particularly end-stage heart failure and other cardiovascular and neurological conditions, as well as healthcare providers seeking innovative and effective treatment options.
Features
- Allogeneic, off-the-shelf cell therapies derived from iPSCs
- Focus on cardiovascular and nervous system diseases
- HiCM-188 cell therapy for the treatment of end-stage heart failure (IND cleared by FDA)
- HiCM-288 program targeting cardiology applications
- HiO-630 program focused on ophthalmology
- HMM-910 and HMM-920 programs targeting motor system diseases